Resource not found


Insuring platform workers against sickness & unemployment 06-12-2021


Updated ESIP study on the social security coverage of platform workers

In January 2019, ESIP published a study titled “Are social security systems adapted to new forms of work created by digital platforms?”  The study raised the question of whether platform workers are covered by social security systems. The main answer was that platform workers can be covered, to a certain extent and are often covered as self-employed workers. 

Since the publication of the first ESIP study, some changes have been introduced in law and/or through Court rulings in several Member States. This might not be sufficient to ensure adequate social protection when platform workers fall under non-standard forms of employment, where formal and more importantly effective access gaps might exist. Issues of work status are expected to be further addressed at EU level through a proposal for a directive to be published by the European Commission.

Promoting the role of social security institutions 06-12-2021


25th anniversary of ESIP

In 2021, ESIP is celebrating 25 years of its existence, 25 years that have been dedicated to promoting the role of social protection systems in the EU. 

Steps towards secure & inclusive digitalisation 03-09-2021


A set of EU digital principles: social security & health insurers’ views

As a follow-up to the Digital Compass Communication of 9 March, the Commission launched a public consultation on the formulation of a set of EU digital principles. These principles would be integrated in a joint declaration of the main EU institutions. ESIP and its Members are committed to and involved in the digitalisation of social security and healthcare systems, with a view to increasing their sustainability and accessibility within and across borders.

Proposals to improve EU rules on rare and paediatric diseases 30-07-2021


ESIP responds to the Public Consultation on the Revision of the OMP and paediatrics Regulations

As part of the legislative initiatives under the Pharmaceutical Strategy for Europe, the Commission opened consultations towards the revision of the EU legislation on medicines for children and rare diseases. ESIP provided its feedback building on the 2019 paper on orphan medicinal products and the previous response to the inception impact assessment